Validation of late recurrence prediction by gene expression profiles and clinicopathological factors in estrogen receptor-positive breast cancer
- 11 June 2024
- journal article
- research article
- Published by Springer Nature in Breast Cancer
- Vol. 31 (5) , 898-908
Abstract
Background The mechanism of late recurrence (LR) of estrogen receptor (ER)-positive breast cancer remains unclear, as previous studies have separately investigated “gene expression profiles” and “clinicopathological factors.” Thus, this study aimed to evaluate the predictive capability of LR by combining the two independent factors of gene expression profiles (42-gene classifier: 42GC) and clinicopathological factors (Clinical Treatment Score post-5 years: CTS5) in multiple large cohorts. Methods We analyzed microarray CEL file data downloaded from public databases of 28 global cohorts. A total of 2,454 patients with ER-positive breast cancer were analyzed for 42GC, and 1,263 of these, with complete clinicopathological data were analyzed for CTS5. Results In the analysis of recurrent patients, the 42GC LR and CTS5 low-risk group tended to have LR. Notably, in the analysis of patients with and without recurrence, the highest LR rate beyond 5 years was observed in the CTS5 high-risk group. The combination of the 42GC and CTS5 high-risk groups showed the highest LR rate (16.9%), significantly exceeding that of the 42GC non-LR (NLR) and CTS5 low-risk combination (5.41%) (p = 0.038, odds ratio = 3.53). Furthermore, incorporating a third factor, 95GC, potentially reduced the number of patients prioritized for extended hormonal therapy for approximately one-quarter of patients. Conclusions Results confirmed that the two factors, gene expression profiles and clinicopathological factors, affect the time of recurrence. It also showed that the biological predisposition for LR (CTS5 low-risk) differed from the high LR rate (CTS5 high-risk). In clinical practice, patients with the 42GC LR and CTS5 high-risk combination should be prioritized for extended hormonal therapy. The addition of CTS5 and 95GC to 42GC allows for better risk classification of LR.Keywords
This publication has 26 references indexed in Scilit:
- Multi-gene classifiers for prediction of recurrence in breast cancer patientsBreast Cancer, 2015
- Markers for the identification of late breast cancer recurrenceBreast Cancer Research, 2015
- Status of adjuvant endocrine therapy for breast cancerBreast Cancer Research, 2014
- Prognostic Relevance of Circulating Tumor Cells in Blood and Disseminated Tumor Cells in Bone Marrow of Patients with Squamous Cell Carcinoma of the Oral CavityClinical Cancer Research, 2014
- Construction of novel immune-related signature for prediction of pathological complete response to neoadjuvant chemotherapy in human breast cancerAnnals of Oncology, 2014
- Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast CancerJNCI: Journal of the National Cancer Institute, 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patientsBreast Cancer Research and Treatment, 2010
- Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifenAnnals of Oncology, 2006
- Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17JNCI: Journal of the National Cancer Institute, 2005